HIV and Women's Health in the United States

HIV affects women differently across the United States. Women acquire HIV most often through vaginal sex, are diagnosed later than men, and remain under-served by PrEP. With early treatment and an undetectable viral load, women with HIV live long lives and don't transmit the virus to partners CDC.

HIV among women in the US: the numbers

About 38,800 people were newly diagnosed with HIV in the US in 2023, and an estimated 1.12 million are living with HIV: of whom roughly 723,000, about two-thirds, are virally suppressed CDC, 2023. Women make up a meaningful share of new diagnoses, and where a woman lives matters. Diagnosis rates cluster in the South and the capital, highest in Washington DC (33 per 100,000), Georgia (26), Florida (23), and Louisiana (23).

Fewer than two-thirds of people living with HIV are virally suppressed, which means a large group either isn't diagnosed, isn't in care, or isn't on steady treatment. For women, those gaps tend to be driven less by individual choices and more by access: to a clinic, to a clinician who raises HIV, and to prevention tools designed and tested in women.

How women acquire HIV (and why some risks are underestimated)

HIV is a virus that attacks the immune system, and only certain body fluids carry it: blood, semen, vaginal fluid, rectal fluid, and breast milk CDC. For most women, transmission happens through vaginal or anal sex; sharing needles or injection equipment is the other major route. The virus doesn't survive long outside the body, so HIV is not spread by saliva, kissing, casual contact, surfaces, food, insects, water, or air.

The risk women most often underestimate is heterosexual vaginal sex. Receptive vaginal sex is a real route of infection, and many women acquire HIV from a long-term partner whose status they didn't know. Because the common picture of HIV in the US has long focused on men, a woman and even her clinician may not flag her risk, so the conversation about testing and prevention never happens. That blind spot is one reason women get diagnosed later.

Why women are often diagnosed later

Acute HIV is easy to miss and highly contagious. Within 2 to 4 weeks of infection Most people develop flu-like symptoms, fever, chills, rash, night sweats, muscle aches, sore throat, fatigue, swollen lymph nodes, mouth ulcers, exactly when the viral load peaks above a million copies/mL and onward transmission is at its highest HHS. These symptoms look exactly like the flu, some people have none at all, and symptoms can neither confirm nor rule out HIV. Only a test does that.

After the acute phase comes clinical latency, often years with no symptoms while the virus stays active. Untreated, HIV eventually progresses to AIDS, the most severe stage, defined by a CD4 count under 200 cells/mm³ or an opportunistic infection. Women are more likely to be diagnosed during this silent stretch, sometimes only when an opportunistic illness appears, because the early window was attributed to a passing virus and no test followed. Early symptoms after a real risk are worth an urgent test rather than a wait-and-see.

Screening and prevention for women (testing, PrEP, pregnancy)

The USPSTF gives HIV screening a Grade A recommendation: screen everyone ages 15–65 at least once, and repeat for those at increased risk, which the CDC frames as at least annually USPSTF. Testing is quick. A finger-stick or oral-swab rapid test gives results in minutes, or a lab blood test is sent off; it's free at many health departments, and at-home kits exist CDC. A negative result is only conclusive after enough time has passed since exposure, so keep that window period in mind. You can read how that timing works on our page about when to test after exposure, or simply get tested and compare testing providers first.

PrEP for women

PrEP is daily or long-acting medicine for people without HIV who are exposed through sex or injection; taken as prescribed it reduces sexual HIV risk by about 99% CDC. One detail matters for women: Descovy is not approved for people at risk through receptive vaginal sex, because its trials didn't include cisgender women. Truvada is approved for all exposure routes, and the long-acting cabotegravir shot (Apretude) is given as two starter doses a month apart, then every two months. Newer twice-yearly injectable lenacapavir produced zero infections among women in the PURPOSE 1 trial, the strongest HIV-prevention result yet WHO. PrEP needs a confirmed negative test before starting and follow-up visits, so see our full PrEP guide for what to expect.

PrEP isn't the only lever. Condoms, regular testing, and a partner on treatment all reduce risk, more on that in preventing HIV without PrEP. If you may have just been exposed, PEP can prevent infection but must start within 72 hours and runs for 28 days, so that's an urgent-care or ER conversation rather than a wait-and-test one CDC.

Pregnancy and perinatal HIV

Perinatal HIV is preventable. With ART during pregnancy and labor plus newborn prophylaxis, the risk of passing HIV to the baby can be reduced to less than 1% CDC. HIV testing is standard in prenatal care, and a positive result during pregnancy is a manageable situation. Because HIV can pass through breast milk, infant feeding is part of that care plan and a conversation to have with your team.

Care considerations specific to women

Everyone diagnosed with HIV should start ART as soon as possible; it's lifelong, and the goal is an undetectable viral load. ART combines medicines from classes like integrase inhibitors, NRTIs, NNRTIs, and protease inhibitors, often as a single daily pill. For women, care folds in reproductive planning, contraception that doesn't interact with the regimen, pregnancy timing, and cervical health, since women with HIV need closer cervical cancer screening. A woman who takes her medicine and stays virally suppressed will not transmit HIV to sex partners, that's U=U CDC.

Disparities among US women

HIV among US women is concentrated by geography and shaped by inequity. The clustering of diagnoses in the South reflects gaps in clinic access, insurance, and prevention reach more than anything biological. Women, especially Black and Latina women, are prescribed PrEP at far lower rates than their share of new diagnoses would warrant, often because the topic is never raised by a clinician who doesn't picture HIV risk in a woman. Closing that gap starts with normalizing the conversation: any woman can ask for an HIV test and ask whether PrEP makes sense for her.

Living well with HIV as a woman

Modern HIV is compatible with a near-normal lifespan. A 20-year-old who starts treatment before her CD4 count falls below 200 now has a life expectancy approaching that of the general population, which is the strongest argument for testing and starting early Lancet HIV. HIV isn't curable; ART controls but doesn't eradicate it, because latent virus reservoirs persist and rebound if treatment stops. The rare documented remissions, including a New York woman, the third case and the first woman (NIH, 2022), came through high-risk stem-cell transplants done to treat cancer and are not a scalable cure. For day-to-day life, the practical questions are often about relationships and telling partners; our guide to disclosing your HIV status walks through that.

Comparing prevention tools for women

When to see a clinician

• You've had a possible exposure within the last 72 hours: go to urgent care or an ER about PEP today, before testing.
• You have flu-like symptoms a few weeks after a sexual risk, ask specifically for HIV testing.
• You're pregnant or planning to be, request HIV testing as part of prenatal care.
• You have ongoing risk through sex or injection and want to discuss PrEP.
• You've never been tested, every adult should be screened at least once.

Keep exploring on EasySTD: whether PrEP is right for you, telling recent partners and HIV/AIDS testing.